摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-1H-isochromene | 1195960-15-6

中文名称
——
中文别名
——
英文名称
1-methyl-1H-isochromene
英文别名
Methyl 1h isochromen
1-methyl-1H-isochromene化学式
CAS
1195960-15-6
化学式
C10H10O
mdl
——
分子量
146.189
InChiKey
WHGBNFULEZIUEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    2-(1-羟乙基)-1-乙炔基苯二(三苯基膦)环戊二烯基氯化钌(II) 作用下, 以 正丁胺 为溶剂, 反应 6.0h, 以60%的产率得到1-methyl-1H-isochromene
    参考文献:
    名称:
    通过催化Ru Vinylidenesnes环芳香异构和双同炔丙基醇的形成:苯并呋喃和异色酮的形成
    摘要:
    钌催化的芳香族均丙和双均丙炔醇的环异构化可有效提供苯并呋喃和异苯并二氢萘。这些(5-和6-过程被证明是化疗和区域选择性内切环化)从关键孺偏二中间体衍生的。胺/铵碱式酸对的存在对于催化循环至关重要。
    DOI:
    10.1021/ol902212h
点击查看最新优质反应信息

文献信息

  • NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
    申请人:Okano Akihiro
    公开号:US20120157459A1
    公开(公告)日:2012-06-21
    [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    提供一个以新型化合物作为活性成分的GPR40激活剂,该化合物具有GPR40激动剂作用,该化合物的盐,该盐或化合物的溶剂合物,或者类似物,尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物:(其中n为0至2;p为0至4;j为0至3;k为0至2;环A是一个芳基团,可选择性被L取代或是一个杂环团,可选择性被L取代;环B是一个苯环、一个吡啶环或一个嘧啶环;X是O,S,—NR7—;R1至R7是特定基团),该化合物的盐,或该盐或化合物的溶剂合物。
  • [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
    申请人:MERCK SHARP & DOHME
    公开号:WO2015160636A1
    公开(公告)日:2015-10-22
    In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    在其多种实施方式中,本发明提供了一类新型的苯甲酰胺化合物,其由式(I)表示,或者其药用可接受的盐或溶剂,或者包含一种或多种所述化合物或其药用可接受的盐或溶剂的药物组合物,并提供了使用所述化合物或其药用可接受的盐或溶剂来治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
  • NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
    申请人:Okano Akihiro
    公开号:US20120220772A1
    公开(公告)日:2012-08-30
    [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH 2 —, O, —S(O) i — (i is 0 to 2), or —NR 7 —; R 1 to R 6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    提供一种GPR40激活剂,其作为活性成分具有一种具有GPR40激动剂作用的新化合物,该化合物的盐、盐或化合物的溶剂或类似物,特别是一种胰岛素分泌促进剂以及预防和/或治疗糖尿病、肥胖或其他疾病的药物。 通过以下公式(I)的化合物解决问题: (其中p为0至4;j为0至3;k为0至2;环A为特定的环状基团;环B为苯环、吡啶环或嘧啶环;X为—CH2—、O、—S(O)i—(i为0至2)或—NR7—;R1至R6为特定的基团),该化合物的盐或盐的溶剂。
  • CYCLIC AMIDE DERIVATIVE
    申请人:Okano Akihiro
    公开号:US20130203739A1
    公开(公告)日:2013-08-08
    [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR 7 —; J 1 is —CR 11a R 11b — or —NR 11c —; J 2 is —CR 12a R 12b — or —NR 12c —; and R 1 to R 12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物,尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂,解决问题的方法是使用Formula (1)的化合物:(其中n为0至2;p为0至4;h为0至3;j为0至3;k为0至2;环B为芳香族或杂环芳基;X为O、S或-NR7-;J1为-CR11aR11b-或-NR11c-;J2为-CR12aR12b-或-NR12c-;R1到R12为特定基团),该化合物的盐,或盐或化合物的溶剂合物。
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
    申请人:OHKOUCHI Munetaka
    公开号:US20120277150A1
    公开(公告)日:2012-11-01
    [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    提供一种包含GPR40激活剂的药剂,其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等,特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物:(其中p为0至4;j为0至2;k为0至1;环A为芳基、杂环基、环烷基、环烯基、螺环基;环B为芳基、杂芳基;X为0或-NR7-;R1至R7和L为特定基团),该化合物的盐或该化合物或盐的溶剂化合物。
查看更多